1 rich Libsyn https://www.libsyn.com 90 600 This is the second episode in our series on cholangiocarcinoma which aims to update clinicians on the latest developments in its diagnosis and management. In this episode, Dr. Marina Baretti discusses the safety of fibroblast growth factor receptor (FGFR) inhibitors, drawing from her clinical experience. She details current safety data, and explains what you need to know about the management of their side effects and adverse events. For more podcast episodes from Karger please visit karger.com/podcasts. This podcast was funded by&amp;nbsp;Taiho&amp;nbsp;Oncology, Inc.&amp;nbsp; The faculty and publisher are solely responsible for this content.&amp;nbsp;Taiho&amp;nbsp;does not recommend or endorse&amp;nbsp; the use of its products other than as described in the approved labeling. The content of this site is not medical advice and does not replace independent medical judgment. &amp;nbsp; Karger - Fast Facts Oncology https://sites.libsyn.com/444057 <iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/27266568/height/90/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/88AA3C/" height="90" width="600" scrolling="no" allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen></iframe> https://assets.libsyn.com/secure/content/154872345